

Andreas Rosenwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1092603/publications.pdf>

Version: 2024-02-01

270
papers

10,627
citations

61687

45
h-index

48101

92
g-index

275
all docs

275
docs citations

275
times ranked

12953
citing authors

#	ARTICLE	IF	CITATIONS
1	⁶⁸ Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. <i>Journal of Nuclear Medicine</i> , 2022, 63, 96-99.	2.8	13
2	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAH trial. <i>British Journal of Haematology</i> , 2022, 196, 116-126.	1.2	9
3	Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. <i>Histopathology</i> , 2022, 80, 381-396.	1.6	10
4	Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. <i>Leukemia</i> , 2022, 36, 760-771.	3.3	14
5	CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. <i>Leukemia and Lymphoma</i> , 2022, 63, 468-472.	0.6	10
6	Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 314-317.	0.7	0
7	Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. <i>HemaSphere</i> , 2022, 6, e672.	1.2	5
8	Epstein-Barr Virus infection patterns in nodular lymphocyte predominant Hodgkin lymphoma. <i>Histopathology</i> , 2022, , .	1.6	6
9	Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice. <i>Autophagy</i> , 2022, 18, 2880-2893.	4.3	3
10	Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 785252.	1.8	2
11	Odronektamab, a human CD20-CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematology</i> , 2022, 9, e327-e339.	2.2	98
12	Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 139-159.	1.4	28
13	A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior. <i>Acta Neurologica Belgica</i> , 2022, , .	0.5	0
14	A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. <i>British Journal of Haematology</i> , 2022, 198, 482-491.	1.2	8
15	EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures. <i>Cancers</i> , 2022, 14, 2176.	1.7	5
16	Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. <i>Hematological Oncology</i> , 2022, 40, 505-517.	0.8	7
17	Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , 1.	3.3	12
18	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	3.3	1,023

#	ARTICLE	IF	CITATIONS
19	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	0.8	17
20	A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type. <i>Annals of Hematology</i> , 2021, 100, 2635-2637.	0.8	1
21	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2224-2232.	1.7	11
22	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021, 137, 2646-2656.	0.6	39
23	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. <i>Haematologica</i> , 2021, 106, 1943-1956.	1.7	46
24	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	3.3	52
25	Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP. <i>Haematologica</i> , 2021, 106, 1684-1692.	1.7	11
26	The impact of <sc>SAMHD1</sc> expression and mutation status in mantle cell lymphoma: An analysis of the <sc>MCL</sc> Younger and Elderly trial. <i>International Journal of Cancer</i> , 2021, 148, 150-160.	2.3	10
27	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. <i>Blood</i> , 2021, 137, 646-660.	0.6	55
28	A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 213-225.	3.2	10
29	Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	15
30	Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. <i>Cancers</i> , 2021, 13, 315.	1.7	7
31	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. <i>Annals of Hematology</i> , 2021, 100, 1537-1546.	0.8	7
32	Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids. <i>PLoS Pathogens</i> , 2021, 17, e1009210.	2.1	16
33	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. <i>Nature Medicine</i> , 2021, 27, 616-619.	15.2	140
34	Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2276.	1.8	4
35	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 133-145.	1.4	12
36	<sc>EBER</sc> in situ hybridization in subcutaneous aluminum granulomas/lymphoid hyperplasia: A diagnostic clue to differentiate injection-associated lymphoid hyperplasia from other forms of pseudolymphomas and cutaneous lymphomas. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 625-631.	0.7	5

#	ARTICLE	IF	CITATIONS
37	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 223-234.	5.1	93
38	Subgroup-Independent Mapping of Renal Cell Carcinomaâ€”Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. <i>Frontiers in Oncology</i> , 2021, 11, 621278.	1.3	31
39	Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 51.	2.8	3
40	Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD). <i>Leukemia and Lymphoma</i> , 2021, 62, 2267-2271.	0.6	0
41	Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , the, 2021, 8, e267-e277.	2.2	18
42	Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. <i>Haematologica</i> , 2021, 106, 2654-2666.	1.7	10
43	A large retroperitoneal lipoblastoma as an incidental finding: a case report. <i>BMC Pediatrics</i> , 2021, 21, 159.	0.7	5
44	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	1.7	44
45	Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. <i>Leukemia</i> , 2021, 35, 2002-2016.	3.3	34
46	Oncogenic Mutations and Gene Fusions in CD30-Positive Lymphoproliferations and Clonally Related Mycosis Fungoides Occurring in the Same Patients. <i>JID Innovations</i> , 2021, 1, 100034.	1.2	5
47	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. <i>Communications Biology</i> , 2021, 4, 799.	2.0	16
48	Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. <i>Leukemia</i> , 2021, 35, 3589-3593.	3.3	8
49	Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 683631.	2.2	5
50	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2417-2426.	1.7	81
51	Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, , .	1.7	11
52	The novel <i>KIT</i> exon 11 germline mutation <i>K558N</i> is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 827-832.	1.5	2
53	Histopathological growth patterns in patients with advanced nodular lymphocyteâ€predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, , .	1.2	4
54	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183.	5.8	26

#	ARTICLE	IF	CITATIONS
55	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6039-6053.	3.2	17
56	Single- and double-hit events in genes encoding immune targets before and after T cell "engaging antibody therapy in MM. <i>Blood Advances</i> , 2021, 5, 3794-3798.	2.5	30
57	The histological and molecular spectrum of lipoblastoma: A case series with identification of three novel gene fusions by targeted RNA-sequencing. <i>Pathology Research and Practice</i> , 2021, 226, 153591.	1.0	4
58	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. <i>Med</i> , 2021, 2, 1171-1193.e11.	2.2	24
59	Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage. <i>Blood Advances</i> , 2021, 5, 4890-4900.	2.5	7
60	Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1107-1115.	0.6	2
61	Targeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation. <i>Cancers</i> , 2021, 13, 5512.	1.7	5
62	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021, 138, 1326-1326.	0.6	1
63	NFATc1/4 and Blimp-1 Support the Follicular and Effector Phenotype of Tregs. <i>Frontiers in Immunology</i> , 2021, 12, 791100.	2.2	3
64	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. <i>Biomedicines</i> , 2021, 9, 1842.	1.4	6
65	ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. <i>Leukemia</i> , 2020, 34, 771-786.	3.3	13
66	RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. <i>Haematologica</i> , 2020, 105, 2316-2326.	1.7	12
67	Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 352-355.	1.1	6
68	The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation. <i>International Journal of Colorectal Disease</i> , 2020, 35, 365-370.	1.0	5
69	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. <i>Blood</i> , 2020, 136, 2851-2863.	0.6	47
70	Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. <i>Blood Advances</i> , 2020, 4, 4451-4462.	2.5	8
71	A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. <i>Haematologica</i> , 2020, 105, 2667-2670.	1.7	20
72	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020, 11, 219.	1.5	23

#	ARTICLE	IF	CITATIONS
73	IKZF1/3 and CRL4 ^{>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i>, 2020, 105, e237-e241.}	1.7	41
74	Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2023-2031.e1.	0.3	10
75	Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines. <i>Cancers</i> , 2020, 12, 455.	1.7	7
76	Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas. <i>Cancer Science</i> , 2020, 111, 749-759.	1.7	16
77	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2020, 6, 872.	3.4	112
78	Interference with ERK-dimerization at the nucleocytoplasmic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. <i>Nature Communications</i> , 2020, 11, 1733.	5.8	38
79	Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles. <i>Blood</i> , 2020, 135, 181-190.	0.6	11
80	Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial. <i>Blood</i> , 2020, 136, 6-7.	0.6	3
81	Inflammation-induced tissue damage mimicking GvHD in human skin models as test-platform for immunotherapeutics. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020, 37, 429-440.	0.9	1
82	Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA). <i>Blood</i> , 2020, 136, 5-6.	0.6	0
83	Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
84	Validation of the <sc>MCL</sc>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , 2019, 184, 616-624.	1.2	25
85	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. <i>Leukemia</i> , 2019, 33, 447-456.	3.3	93
86	Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. <i>Annals of Hematology</i> , 2019, 98, 515-517.	0.8	2
87	The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1208-1213.	2.0	25
88	Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. <i>Blood Cancer Journal</i> , 2019, 9, 67.	2.8	5
89	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	51
90	Isolated Intraocular Rosai-Dorfman Disease. <i>Ocular Oncology and Pathology</i> , 2019, 5, 418-423.	0.5	3

#	ARTICLE	IF	CITATIONS
91	A Supraclavicular ALK-Positive Anaplastic Large-Cell Lymphoma Initially Misdiagnosed and Yet Successfully Treated with Wide Excision and Adjuvant Chemotherapy: a Case Report. SN Comprehensive Clinical Medicine, 2019, 1, 716-725.	0.3	2
92	Positron Emission Tomographyâ€‘Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology, 2019, 37, 2835-2845.	0.8	151
93	Cognate Nonlytic Interactions between CD8+ T Cells and Breast Cancer Cells Induce Cancer Stem Cellâ€‘like Properties. Cancer Research, 2019, 79, 1507-1519.	0.4	31
94	Prognostic value of tumour-infiltrating CD8+â€‘lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?. Cancer Immunology, Immunotherapy, 2019, 68, 563-575.	2.0	22
95	The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes. Cell Reports, 2019, 27, 3533-3546.e7.	2.9	45
96	Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes. Journal of Molecular Biology, 2019, 431, 2884-2893.	2.0	21
97	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica, 2019, 104, e562-e565.	1.7	38
98	A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. Haematologica, 2019, 104, e460-e464.	1.7	5
99	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nature Communications, 2019, 10, 1459.	5.8	99
100	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood, 2019, 133, 1664-1676.	0.6	184
101	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, The, 2019, 394, 2271-2281.	6.3	155
102	Memory CD4+ T cells lacking expression of CCR7 promote pro-inflammatory cytokine production in patients with diffuse cutaneous systemic sclerosis. European Journal of Dermatology, 2019, 29, 468-476.	0.3	9
103	The identification of patientâ€‘specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wildâ€‘type melanomas. Cancer, 2019, 125, 586-600.	2.0	16
104	Hexokinase-2 Expression in ¹¹C-Methionineâ€‘Positive, ¹⁸F-FDGâ€‘Negative Multiple Myeloma. Journal of Nuclear Medicine, 2019, 60, 348-352.	2.8	21
105	Differential expression of long nonâ€‘coding <sc>RNA</sc>s are related to proliferation and histological diversity in follicular lymphomas. British Journal of Haematology, 2019, 184, 373-383.	1.2	12
106	Doubling rituximab in highâ€‘risk patients with aggressive Bâ€‘cell lymphoma â€‘results of the <sc>DENSE</sc>â€‘â€‘Mega<sc>CHOEP</sc> trial. British Journal of Haematology, 2019, 184, 760-768.	1.2	9
107	Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma. Blood, 2019, 133, 377-380.	0.6	22
108	Potential influence of concomitant chemotherapy on <sc>CXCR</sc>4 expression in receptor directed endoradiotherapy. British Journal of Haematology, 2019, 184, 440-443.	1.2	25

#	ARTICLE	IF	CITATIONS
109	Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 3090.	2.2	39
110	<i>RSPO2</i> gene rearrangement: a powerful driver of β -catenin activation in liver tumours. <i>Gut</i> , 2019, 68, 1287-1296.	6.1	29
111	Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL). <i>Blood</i> , 2019, 134, 236-236.	0.6	9
112	Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma) Tj ETQq0 0 0 rgBT/Overlack 10 Tf 50	0.6	0
113	Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or) Tj ETQq1 1 0,784314 rgBT/Over	0.6	0
114	First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidationâ€”Final results of the AATT study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7503-7503.	0.8	10
115	Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4085-4085.	0.6	0
116	Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients. <i>Blood</i> , 2019, 134, 5448-5448.	0.6	0
117	T-cell repertoires in refractory coeliac disease. <i>Gut</i> , 2018, 67, gutjnl-2016-311816.	6.1	21
118	Methotrexate-induced lymphoproliferative disorders: regression matters. <i>Leukemia and Lymphoma</i> , 2018, 59, 1027-1029.	0.6	1
119	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
120	Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1573-1581.	0.3	41
121	Identification of <i>Candida albicans</i> regulatory genes governing mucosal infection. <i>Cellular Microbiology</i> , 2018, 20, e12841.	1.1	23
122	Next-Generation Sequencing for Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 163-165.	1.2	3
123	CD40L mediated alternative NF κ B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. <i>Cell Death and Disease</i> , 2018, 9, 86.	2.7	23
124	The exomic landscape of t(14;18)â€”negative diffuse follicular lymphoma with 1p36 deletion. <i>British Journal of Haematology</i> , 2018, 180, 391-394.	1.2	24
125	CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells. <i>Journal of the Neurological Sciences</i> , 2018, 385, 96-98.	0.3	7
126	Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphomaâ€”a feasibility study using full slide staining. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 341-349.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
128	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. <i>Haematologica</i> , 2018, 103, 1182-1190.	1.7	34
129	[¹¹ C]Methionine emerges as a new biomarker for tracking active myeloma lesions. <i>British Journal of Haematology</i> , 2018, 181, 701-703.	1.2	13
130	SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Modern Pathology</i> , 2018, 31, 505-516.	2.9	31
131	Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. <i>Haematologica</i> , 2018, 103, 116-125.	1.7	48
132	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. <i>Blood</i> , 2018, 131, 417-420.	0.6	108
133	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018, 131, 226-235.	0.6	31
134	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4511-4523.	1.8	92
135	Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. <i>Blood</i> , 2018, 132, 2744-2753.	0.6	27
136	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
137	Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under <i>Viscum album</i> Extracts After Resistance to R-CHOP: A Case Report. <i>Anticancer Research</i> , 2018, 38, 5363-5369.	0.5	8
138	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	0.6	89
139	The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. <i>British Journal of Haematology</i> , 2018, 183, 225-234.	1.2	24
140	TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells. <i>Nature Communications</i> , 2018, 9, 3115.	5.8	58
141	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018, 132, 1695-1702.	0.6	49
142	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. <i>Nature Communications</i> , 2018, 9, 2378.	5.8	72
143	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	13.7	276
144	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	0.6	19

#	ARTICLE	IF	CITATIONS
145	Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials. <i>Blood</i> , 2018, 132, 1622-1622.	0.6	14
146	Prognostic Significance of MYC Single, Double, Triple Hit and MYC-Translocation Partner Status in Diffuse Large B-Cell Lymphoma - a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC). <i>Blood</i> , 2018, 132, 344-344.	0.6	13
147	PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group. <i>Blood</i> , 2018, 132, 925-925.	0.6	12
148	Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease. <i>Blood</i> , 2018, 132, 4455-4455.	0.6	3
149	PARP14 Is a Novel Therapeutic Target in STAT6 mutant Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2842-2842.	0.6	1
150	Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.. <i>Blood</i> , 2018, 132, 3217-3217.	0.6	0
151	FcmR Shapes BCR Signaling in IgM-Positive Leukemia. <i>Blood</i> , 2018, 132, 2620-2620.	0.6	0
152	The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5132-5132.	0.6	0
153	The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacidine in Secondary AML. <i>Blood</i> , 2018, 132, 5148-5148.	0.6	0
154	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial. <i>Blood</i> , 2018, 132, 4096-4096.	0.6	0
155	A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Blood</i> , 2018, 132, 343-343.	0.6	0
156	CXCR4 PET/CT Scan Is Superior to FDG PET/CT Scan in Accurately Defining Marginal Zone Lymphoma Nodal and Extranodal Involvement. <i>Blood</i> , 2018, 132, 2881-2881.	0.6	1
157	Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. <i>Blood</i> , 2018, 132, 4188-4188.	0.6	0
158	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
159	B-cell lymphomas with discordance between pathological features and clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 439-451.	1.4	5
160	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. <i>Blood</i> , 2017, 130, 323-327.	0.6	69
161	<i><i>TP53</i></i> mutation and survival in aggressive B cell lymphoma. <i>International Journal of Cancer</i> , 2017, 141, 1381-1388.	2.3	69
162	An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 1922-1930.	0.6	12

#	ARTICLE	IF	CITATIONS
163	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. <i>Blood</i> , 2017, 129, 333-346.	0.6	57
164	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. <i>Blood</i> , 2017, 129, 598-608.	0.6	20
165	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	1.8	79
166	The clinicopathologic spectrum of mature aggressive B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 453-466.	1.4	27
167	Dermatopathic lymphadenopathy with Langerhans cell chimerism in graft-versus-host disease of the skin. <i>European Journal of Haematology</i> , 2017, 99, 582-585.	1.1	1
168	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , 2017, 130, 1819-1831.	0.6	62
169	Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 467-489.	1.4	59
170	First case of human peritoneal cysticercosis mimicking peritoneal carcinosis: necessity of laparoscopy and histologic assessment for the correct diagnosis. <i>JMM Case Reports</i> , 2017, 4, e005097.	1.3	9
171	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. <i>Oncotarget</i> , 2017, 8, 9323-9338.	0.8	27
172	Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?. <i>Oncotarget</i> , 2017, 8, 96732-96737.	0.8	17
173	Clinical Significance of Disseminated Pluripotent Tumor Cell Signature Expression in the Bone Marrow from Patients with Colorectal Cancer. <i>Journal of Cancer Science & Therapy</i> , 2017, 9, 669-674.	1.7	0
174	Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2016, 12, 2942-2947.	0.8	7
175	Targeting protein kinase C in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 394-403.	1.2	10
176	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2016, 128, 2666-2670.	0.6	82
177	Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. <i>Haematologica</i> , 2016, 101, 1380-1389.	1.7	43
178	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	7.7	93
179	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. <i>Blood</i> , 2016, 128, 1101-1111.	0.6	115
180	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	0.6	177

#	ARTICLE	IF	CITATIONS
181	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <i>Haematologica</i> , 2016, 101, 1002-1009.	1.7	43
182	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. <i>Clinical Cancer Research</i> , 2016, 22, 4341-4349.	3.2	43
183	Novel <i>IGH</i> and <i>MYC</i> Translocation Partners in Diffuse Large B-Cell Lymphomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 932-943.	1.5	10
184	Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases. <i>Oncology and Therapy</i> , 2016, 4, 199-210.	1.0	16
185	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 851-862.	3.3	50
186	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. <i>BMC Cancer</i> , 2016, 16, 115.	1.1	17
187	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
188	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. <i>Leukemia and Lymphoma</i> , 2016, 57, 563-571.	0.6	34
189	The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl. <i>Blood</i> , 2016, 128, 151-151.	0.6	2
190	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2686-2686.	0.6	1
191	Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib. <i>Blood</i> , 2016, 128, 3282-3282.	0.6	7
192	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.	0.6	1
193	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7500-7500.	0.8	13
194	Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 38762-38774.	0.8	3
195	B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 611-611.	0.6	0
196	<i>IRF1</i> Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 609-609.	0.6	0
197	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. <i>Blood</i> , 2016, 128, 4095-4095.	0.6	0
198	Molecular Features of Germinal Cell Derived B-Cell Lymphomas Using miRNA Signatures. <i>Blood</i> , 2016, 128, 5288-5288.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance. <i>Blood</i> , 2016, 128, 4512-4512.	0.6	0
200	IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2015, 126, 1741-1752.	0.6	184
201	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	0.6	110
202	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. <i>Blood</i> , 2015, 125, 124-132.	0.6	79
203	The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells. <i>Haematologica</i> , 2015, 100, e458-e461.	1.7	13
204	Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. <i>Blood</i> , 2015, 126, 437-444.	0.6	29
205	A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer. <i>Cancer Cell</i> , 2015, 28, 743-757.	7.7	122
206	GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. <i>Haematologica</i> , 2015, 100, 377-384.	1.7	64
207	Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1125-1130.	3.3	49
208	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , The, 2015, 16, 1111-1122.	5.1	483
209	Repression of <sc>SRF</sc> target genes is critical for <sc>M</sc> yâ€dependent apoptosis of epithelial cells. <i>EMBO Journal</i> , 2015, 34, 1554-1571.	3.5	30
210	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
211	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13447-13454.	3.3	143
212	Alleleâ€specific <sc>PCR</sc> is a powerful tool for the detection of the <i><sc>MYD</sc>88</i> L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. <i>British Journal of Haematology</i> , 2015, 171, 145-148.	1.2	14
213	MINCR is a MYC-induced lncRNA able to modulate MYCâ€™s transcriptional network in Burkitt lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5261-70.	3.3	91
214	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2015, 156, 3895-3908.	1.4	153
215	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 333-333.	0.6	7
216	Numerical and Structural Genomic Aberrations Are Reliably Detectable in Tissue Microarrays of Formalin-Fixed Paraffin-Embedded Tumor Samples by Fluorescence In-Situ Hybridization. <i>PLoS ONE</i> , 2014, 9, e95047.	1.1	16

#	ARTICLE	IF	CITATIONS
217	Impact of miR-21, miR-126 and miR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava. PLoS ONE, 2014, 9, e109877.	1.1	42
218	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. OncoTargets and Therapy, 2014, 7, 1123.	1.0	7
219	Loss of signalling via Gl \pm 13 in germinal centre B-cell-derived lymphoma. Nature, 2014, 516, 254-258.	13.7	253
220	Fluorescence in situ analysis of soft tissue tumor associated genetic alterations in formalin-fixed paraffin-embedded tissue. Pathology Research and Practice, 2014, 210, 804-811.	1.0	10
221	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2014, 15, 1090-1099.	5.1	315
222	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Human Pathology, 2014, 45, 2144-2153.	1.1	34
223	Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. Pathology Research and Practice, 2014, 210, 369-376.	1.0	10
224	Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncology Reports, 2014, 31, 1059-1066.	1.2	18
225	Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation. PLoS ONE, 2013, 8, e81320.	1.1	6
226	A Monoclonal IgM Antibody With Specificity To Heat Shock Protein GRP78/BIP Shows Anti- Myeloma Activity In Vitro and In Vivo, Synergy In Combination With Lenalidomide and Safety In a Pilot Phase I Study. Blood, 2013, 122, 3213-3213.	0.6	0
227	Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab. Blood, 2013, 122, 1631-1631.	0.6	0
228	Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma. Blood, 2013, 122, 4253-4253.	0.6	4
229	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue " An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	0.6	0
230	Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma.. Blood, 2012, 120, 2677-2677.	0.6	3
231	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. Blood, 2012, 120, 679-679.	0.6	2
232	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545.	0.6	0
233	TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricovera-60 Trial. Blood, 2012, 120, 546-546.	0.6	0
234	Telomere Length in Mantle Cell Lymphoma.. Blood, 2012, 120, 2509-2509.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. <i>Blood</i> , 2011, 118, 435-435.	0.6	0
236	BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). <i>Blood</i> , 2011, 118, 2634-2634.	0.6	0
237	Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study. <i>Blood</i> , 2010, 116, 993-993.	0.6	8
238	Proteasome Inhibition Leads to Dephosphorylation and Downregulation of Protein Expression of Members of the Akt/mTOR Pathway In MCL. <i>Blood</i> , 2010, 116, 4449-4449.	0.6	0
239	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	0.6	2
240	Enzastaurin Treatment Affects Multiple Regulatory Pathways at Transcriptome and Cellular Proteome Level of Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 2893-2893.	0.6	0
241	Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs. <i>Blood</i> , 2010, 116, 52-52.	0.6	0
242	Deregulation of miRNAs by Epigenetic Silencing Disrupts Suppression of the Oncogene PLAG1 in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3463-3463.	0.6	0
243	Is there still a point for classical cytogenetic banding analysis in the diagnostic work-up of specimens suspicious for lymphoma?. <i>Leukemia and Lymphoma</i> , 2008, 49, 6-7.	0.6	2
244	Spectral Karyotyping and SNP Microarray Analysis Define Uniparental Disomy (UPD) as a Novel Mutational Mechanism in MSI- and CSI-Colorectal Cancers. <i>Analytical Cellular Pathology</i> , 2008, 30, 507-507.	0.7	0
245	CLLU1 expression: The latest risk predictor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1665-1666.	0.6	0
246	High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation.. <i>Blood</i> , 2007, 110, 342-342.	0.6	0
247	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. <i>Blood</i> , 2007, 110, 360-360.	0.6	7
248	SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. <i>Blood</i> , 2007, 110, 1585-1585.	0.6	0
249	Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): A feature of B-CLL sub-sets with poor prognosis genetic alterations?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2263-2264.	0.6	3
250	Comprehensive Analysis of Homeobox Genes in Hodgkin Lymphoma Cell Lines Identified Dysregulated Expression of HOXB9 Mediated by Constitutive Active ERK5 Signalling Pathway and BMI1.. <i>Blood</i> , 2006, 108, 471-471.	0.6	0
251	Altered Cellular Protein Levels of Tumor Suppressor Genes and Heat Shock Elements (TRAP1) Indicate Sensitivity to the Proteasome Inhibitor Bortezomib (Velcade®) in Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2424-2424.	0.6	14
252	Genetic Rearrangements of FOXP1 Are Restricted to a Subset of Aggressive B Cell Lymphoma with Extranodal Presentation.. <i>Blood</i> , 2005, 106, 2837-2837.	0.6	7

#	ARTICLE	IF	CITATIONS
253	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. Blood, 2004, 104, 415-415.	0.6	1
254	DNA microarrays in lymphoid malignancies. Oncology, 2003, 17, 1743-8; discussion 1750, 1755, 1758-9 passim.	0.4	3
255	Gene expression profiling in lymphoid malignancies. , 2001, , 162-186.		0
256	Hodgkin's lymphoma. , 2001, , 89-110.		0
257	Pathology and cytogenetics. , 2001, , 12-18.		0
258	Follicular lymphoma. , 2001, , 111-125.		0
259	MALT lymphoma and other marginal zone lymphomas. , 2001, , 126-140.		0
260	Small lymphocytic lymphoma and its variants. , 2001, , 141-153.		0
261	Mantle cell lymphoma. , 2001, , 154-167.		2
262	Diffuse large B-cell lymphoma. , 2001, , 168-181.		0
263	Burkitt's and lymphoblastic lymphomas. , 2001, , 182-199.		0
264	T-cell lymphoma. , 2001, , 215-232.		0
265	Cutaneous lymphoma. , 2001, , 233-251.		0
266	Lymphoma in the immunosuppressed. , 2001, , 252-265.		0
267	Central nervous system lymphoma. , 2001, , 200-214.		1
268	A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. , 2000, 27, 52-58.		67
269	A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral t-cell lymphomas?. , 1999, 26, 210-214.		36
270	Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas. , 1998, 22, 114-121.		40